Oncology

Even healthy breast tissue harbors rare populations of mutated epithelial cells, raising important questions about their role in breast cancer development.

A randomized clinical trial has revealed that pharmacological ascorbate (high-dose intravenous vitamin C) improves survival outcomes for patients with metastatic pancreatic cancer, a disease with notoriously low 5-year survival rates.

CAR T-cell therapy, a major advancement in treating hematologic cancers, has struggled to show consistent success in solid tumors.

A new Phase III clinical trial has revealed that combining nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) improves progression-free survival in patients with Stage III or IV classic Hodgkin’s lymphoma compared to the standard brentuximab vedotin with AVD (BV+AVD).

A recent study has spotlighted the regulatory divide between the US Food and Drug Administration’s (FDA) Accelerated Approval (AA) pathway and the European Medicines Agency’s (EMA) Conditional Marketing Authorization (CMA) process, showing stark differences in their cancer drug approvals.

Overtreatment of prostate cancer persists among men with limited life expectancy within the Veterans Affairs (VA) health system.

A genetic variant, the BIM deletion polymorphism (BDP), has been identified by researchers to significantly enhance leukemia stem and progenitor cells’ survival, making them resistant to common targeted therapies.

A powerful link between health insurance status and racial and ethnic disparities in advanced cancer diagnoses has been identified in a recently published study.